Peptide Drug Conjugate Development

Peptide drug conjugates (PDCs) represent a promising frontier in targeted cancer therapy, particularly in the context of inhibiting poly(ADP-ribose) polymerase (PARP). At Alfa Cytology, we specialize in the development of innovative peptide drug conjugates for various therapeutic applications, including the inhibition of PARP.

Introduction to Peptide Drug Conjugate for Inhibiting PARP

PARP enzymes play a crucial role in DNA repair mechanisms, particularly in the repair of single-strand breaks. Inhibition of PARP has garnered significant attention due to its potential to enhance the efficacy of existing chemotherapeutic agents and to exploit the synthetic lethality concept in tumors with defective DNA repair pathways, such as those harboring BRCA1 or BRCA2 mutations.

Fig. 1 Schematic structure of receptor targeting drug conjugates. (Hoppenz P., et al. 2020)

PDCs combine the specificity of peptides with the therapeutic potential of cytotoxic agents, allowing for targeted delivery to cancer cells while minimizing off-target effects. By leveraging the unique properties of peptides, such as their ability to bind selectively to specific receptors overexpressed in tumor cells, PDCs can effectively enhance drug accumulation in the desired tissues. This targeted approach not only improves the therapeutic index of the conjugated drug but also reduces systemic toxicity, a significant advantage over conventional chemotherapy.

Our Services

At Alfa Cytology, we specialize in the development of innovative peptide drug conjugates for various therapeutic applications, including the inhibition of PARP. Our full suite of services covers multiple stages of PDC development for PARP inhibition, from conceptualization to preclinical validation.

Advantages of PDCs

We offer a customizable approach, allowing you to select from our comprehensive services tailored to your project needs. Whether you require peptide library screening, linker design and optimization, conjugation chemistry, or characterization and quality control, our team is ready to support your specific objectives. To discuss potential collaborative opportunities, please don't hesitate to contact us.

For research use only. Not intended for any clinical use.